Jessica H. Maxwell
University of Pittsburgh
Network
Latest external collaboration on country level. Dive into details by clicking on the dots.
Publication
Featured researches published by Jessica H. Maxwell.
Clinical Cancer Research | 2010
Jessica H. Maxwell; Bhavna Kumar; Felix Y. Feng; Francis P. Worden; Julia S. Lee; Avraham Eisbruch; Gregory T. Wolf; Mark E. Prince; Jeffrey S. Moyer; Theodoros N. Teknos; Douglas B. Chepeha; Jonathan B. McHugh; Susan G. Urba; Jay Stoerker; Heather M. Walline; David M. Kurnit; Kitrina G. Cordell; Samantha J. Davis; Preston D. Ward; Carol R. Bradford; Thomas E. Carey
Purpose: The goal of this study was to examine the effect of tobacco use on disease recurrence (local/regional recurrence, distant metastasis, or second primary) among patients with human papillomavirus (HPV)–positive squamous cell carcinoma of the oropharynx (SCCOP) following a complete response to chemoradiation therapy. Experimental Design: Between 1999 and 2007, 124 patients with advanced SCCOP (86% with stage IV) and adequate tumor tissue for HPV analysis who were enrolled in one of two consecutive University of Michigan treatment protocols were prospectively included in this study. Patients were categorized as never-, former, or current tobacco users. The primary end points were risk of disease recurrence and time to recurrence; secondary end points were disease-specific survival and overall survival. Results: One hundred and two patients (82.3%) had HPV-positive tumors. Over two thirds (68%) of patients with HPV-positive tumors were tobacco users. Among HPV-positive patients, current tobacco users were at significantly higher risk of disease recurrence than never-tobacco users (hazard ratio, 5.2; confidence interval, 1.1-24.4; P = 0.038). Thirty-five percent of HPV-positive ever tobacco users recurred compared with only 6% of HPV-positive never users and 50% of HPV-negative patients. All HPV-negative patients were tobacco users and had significantly shorter times to recurrence (P = 0.002), and had reduced disease-specific survival (P = 0.004) and overall survival (P < 0.001) compared with HPV-positive patients. Compared with HPV-positive never-tobacco users, those with a tobacco history showed a trend for reduced disease-specific survival (P = 0.064) but not overall survival (P = 0.221). Conclusions: Current tobacco users with advanced, HPV-positive SCCOP are at higher risk of disease recurrence compared with never-tobacco users. Clin Cancer Res; 16(4); 1226–35
Cancer | 2013
Jessica H. Maxwell; Robert L. Ferris; William E. Gooding; Diana E. Cunningham; Vikas Mehta; Seungwon Kim; Eugene N. Myers; Jonas T. Johnson; Simion I. Chiosea
Extracapsular spread (ECS) in cervical lymph node metastases from head and neck squamous cell carcinoma (SCC) is regarded as an adverse prognostic factor and is often used to select patients who may benefit from adjuvant therapy. The prognostic value of ECS was evaluated for patients with oropharyngeal SCC (OPC; with known p16/human papillomavirus [HPV] status) and for patients with SCC of the oral cavity (OCC).
Clinical Cancer Research | 2012
Malabika Sen; Sonali Joyce; Mary C. Panahandeh; Changyou Li; Sufi M. Thomas; Jessica H. Maxwell; Lin Wang; William E. Gooding; Daniel E. Johnson; Jennifer R. Grandis
Purpose: EGF receptor (EGFR) is upregulated in most epithelial cancers where signaling through EGFR contributes to cancer cell proliferation and survival. The limited clinical efficacy of EGFR inhibitors suggests that identification of resistance mechanisms may identify new pathways for therapeutic targeting. STAT3 is upregulated in many cancers and activated via both EGFR-dependent and -independent pathways. In the present study, we tested the consequences of STAT3 inhibition in EGFR inhibitor–resistant head and neck squamous cell carcinoma (HNSCC) and bladder cancer models to determine whether STAT3 blockade can enhance responses to EGFR targeting. Experimental Design: pSTAT3 expression was assessed in human HNSCC tumors that recurred following cetuximab treatment. Cetuximab-sensitive and -resistant cell lines were treated with a STAT3 decoy to determine EC50 concentrations and the effects on STAT3 target gene expression by Western blotting. In vivo assays included evaluation of antitumor efficacy of STAT3 decoy in cetuximab-sensitive and -resistant models followed by immunoblotting for STAT3 target protein expression. Results: Targeting STAT3 with a STAT3 decoy reduced cellular viability and the expression of STAT3 target genes in EGFR inhibitor resistance models. The addition of a STAT3 inhibitor to EGFR blocking strategies significantly enhanced antitumor effects in vivo. Biopsies from HNSCC tumors that recurred following cetuximab treatment showed increased STAT3 activation compared with pretreatment biopsies. Conclusions: These results suggest that STAT3 activation contributes to EGFR inhibitor resistance both in HNSCC and bladder cancer where concomitant targeting of STAT3 may represent an effective treatment strategy. Clin Cancer Res; 18(18); 4986–96. ©2012 AACR.
Head and Neck-journal for The Sciences and Specialties of The Head and Neck | 2009
Jessica H. Maxwell; Bhavna Kumar; Felix Y. Feng; Jonathan B. McHugh; Kitrina G. Cordell; Avraham Eisbruch; Francis P. Worden; Gregory T. Wolf; Mark E. Prince; Jeffrey S. Moyer; Theodoros N. Teknos; Douglas B. Chepeha; Jay Stoerker; Heather M. Walline; Thomas E. Carey; Carol R. Bradford
Human papillomavirus (HPV) has been detected in keratinizing nasopharyngeal carcinomas (NPCs); however, the relationship between HPV and Epstein–Barr virus (EBV) among whites with nonkeratinizing NPCs remains unclear. The HPV, p16, and EBV status was examined in current University of Michigan patients with NPC.
Laryngoscope | 2014
Jessica H. Maxwell; Vikas Mehta; Hong Wang; Diana E. Cunningham; Umamaheswar Duvvuri; Seungwon Kim; Jonas T. Johnson; Robert L. Ferris
To determine posttreatment quality of life (QOL) in head and neck cancer patients, stratifying by human papillomavirus (HPV)/p16 status and primary treatment modality.
BMC Cancer | 2013
Simion I. Chiosea; Jennifer R. Grandis; Vivian Wai Yan Lui; Brenda Diergaarde; Jessica H. Maxwell; Robert L. Ferris; Seungwon Kim; Alyssa Luvison; Megan A. Miller; Marina N. Nikiforova
BackgroundRecent genomic evidence suggests frequent phosphatidylinositide 3-kinase (PI3K) pathway activation in human papillomavirus (HPV) positive oropharyngeal squamous cell carcinoma. Mutations/amplification of the gene encoding p110α catalytic subunit of phosphoinositide 3-kinase (PIK3CA), loss of phosphatase and tensin homolog (PTEN) and HRAS mutations are known to activate PI3K pathway.Methods and resultsPIK3CA mutations were identified by Sanger sequencing in 23 of 75 (31%) HPV-positive oropharyngeal carcinomas, including exon 9 (p.E545K [n = 10] and p.E542K [n = 5]) or exon 20 (p.H1047Y, n = 2) mutations. Five rare and one novel (p.R537Q) PIK3CA mutations were identified. HRAS mutation (p.Q61L) was detected in 1 of 62 tested cases. PIK3CA amplification by fluorescence in situ hybridization (FISH) was identified in 4 cases (4/21, 20%), while PTEN loss was seen in 7 (7/21, 33%) cases (chromosome 10 monosomy [n = 4], homozygous deletion [n = 3]).ConclusionsOverall, genetic alterations that likely lead to PI3K pathway activation were identified in 34 of 75 cases (45%) and did not correlate with disease specific survival. These findings offer a molecular rationale for therapeutic targeting of PI3K pathway in patients with HPV-positive oropharyngeal carcinoma.
Archives of Otolaryngology-head & Neck Surgery | 2015
Jessica H. Maxwell; Lester D. R. Thompson; Margaret Brandwein-Gensler; Bernhard G. Weiss; Martin Canis; Bibianna Purgina; Arpan V. Prabhu; Chi Lai; Yongli Shuai; William R. Carroll; Anthony Morlandt; Umamaheswar Duvvuri; Seungwon Kim; Jonas T. Johnson; Robert L. Ferris; Raja R. Seethala; Simion I. Chiosea
IMPORTANCE Positive margins are associated with poor prognosis among patients with oral tongue squamous cell carcinoma (SCC). However, wide variation exists in the margin sampling technique. OBJECTIVE To determine the effect of the margin sampling technique on local recurrence (LR) in patients with stage I or II oral tongue SCC. DESIGN, SETTING, AND PARTICIPANTS A retrospective study was conducted from January 1, 1986, to December 31, 2012, in 5 tertiary care centers following tumor resection and elective neck dissection in 280 patients with pathologic (p)T1-2 pN0 oral tongue SCC. Analysis was conducted from June 1, 2013, to January 20, 2015. INTERVENTIONS In group 1 (n = 119), tumor bed margins were not sampled. In group 2 (n = 61), margins were examined from the glossectomy specimen, found to be positive or suboptimal, and revised with additional tumor bed margins. In group 3 (n = 100), margins were primarily sampled from the tumor bed without preceding examination of the glossectomy specimen. The margin status (both as a binary [positive vs negative] and continuous [distance to the margin in millimeters] variable) and other clinicopathologic parameters were compared across the 3 groups and correlated with LR. MAIN OUTCOMES AND MEASURES Local recurrence. RESULTS Age, sex, pT stage, lymphovascular or perineural invasion, and adjuvant radiation treatment were similar across the 3 groups. The probability of LR-free survival at 3 years was 0.9 and 0.8 in groups 1 and 3, respectively (P = .03). The frequency of positive glossectomy margins was lowest in group 1 (9 of 117 [7.7%]) compared with groups 2 and 3 (28 of 61 [45.9%] and 23 of 95 [24.2%], respectively) (P < .001). Even after excluding cases with positive margins, the median distance to the closest margin was significantly narrower in group 3 (2 mm) compared with group 1 (3 mm) (P = .008). The status (positive vs negative) of margins obtained from the glossectomy specimen correlated with LR (P = .007), while the status of tumor bed margins did not. The status of the tumor bed margin was 24% sensitive (95% CI, 16%-34%) and 92% specific (95% CI, 85%-97%) for detecting a positive glossectomy margin. CONCLUSIONS AND RELEVANCE The margin sampling technique affects local control in patients with oral tongue SCC. Reliance on margin sampling from the tumor bed is associated with worse local control, most likely owing to narrower margin clearance and greater incidence of positive margins. A resection specimen-based margin assessment is recommended.
Clinical Cancer Research | 2011
Neil E. Bhola; Sufi M. Thomas; Maria L. Freilino; Sonali Joyce; Anirban Sahu; Jessica H. Maxwell; Athanassios Argiris; Raja R. Seethala; Jennifer R. Grandis
Purpose: Epidermal growth factor receptor (EGFR) overexpression is correlated with decreased survival in head and neck cancer (HNC) where the addition of EGFR inhibition to standard chemoradiation approaches has improved treatment responses. However, the basis for the limited efficacy of EGFR inhibitors in HNC is incompletely understood. G-protein–coupled receptors (GPCR) have been shown to be overexpressed in HNC where GPCR activation induces HNC growth via both EGFR-dependent and -independent pathways. We hypothesized that targeting GPCR-induced EGFR-independent signaling would improve the efficacy of EGFR inhibition. Experimental Design: Using a high-throughput phosphoproteome array, we identified proteins that were phosphorylated in HNC cells where EGFR expression was downmodulated by RNA interference (RNAi) in the presence or absence of a GPCR ligand. We confirmed the findings from the array by Western blotting followed by in vitro and in vivo phenotypic assays. Results: p70S6K phosphorylation was elevated approximately sixfold in EGFR siRNA-transfected cells treated with a GPCR ligand. In addition to RNAi-mediated EGFR downmodulation, GPCR-mediated phosphorylation of p70S6K was modestly increased by EGFR inhibitor cetuximab approved by the Food and Drug Administration. Biopsies from cetuximab-treated patients also displayed increased phospho-p70S6K staining compared with pretreatment biopsies. HNC cells were growth inhibited by both genetic and pharmacologic p70S6K targeting strategies. Furthermore, p70S6K targeting in combination with cetuximab resulted in enhanced antitumor effects in both in vitro and in vivo HNC models. Conclusions: These results indicate that increased phosphorylation of p70S6K in cetuximab-treated patients may be due to increased GPCR signaling. Therefore, the addition of p70S6K targeting strategies may improve treatment responses to EGFR inhibition. Clin Cancer Res; 17(15); 4996–5004. ©2011 AACR.
Head and Neck-journal for The Sciences and Specialties of The Head and Neck | 2014
Irina Y. Dobrosotskaya; Emily Bellile; Matthew E. Spector; Bhavna Kumar; Felix Y. Feng; Avraham Eisbruch; Gregory T. Wolf; Mark E. Prince; Jeffrey S. Moyer; Theodoros N. Teknos; Douglas B. Chepeha; Heather M. Walline; Jonathan B. McHugh; Kitrina G. Cordell; P. Daniel Ward; Serena A. Byrd; Jessica H. Maxwell; Susan G. Urba; Carol R. Bradford; Thomas E. Carey; Francis P. Worden
Optimal treatment for locally advanced squamous cell carcinoma of the oropharynx (SCCOP) is not well defined. Here we retrospectively compare survival and toxicities from 2 different organ preservation protocols.
Head and Neck-journal for The Sciences and Specialties of The Head and Neck | 2013
Anna M. Eliassen; Samantha J. Hauff; Alice L. Tang; Dafydd H. Thomas; Jonathan B. McHugh; Heather M. Walline; Jay Stoerker; Jessica H. Maxwell; Francis P. Worden; Avraham Eisbruch; Michael J. Czerwinski; Silvana Papagerakis; Douglas B. Chepeha; Carol R. Bradford; David A. Hanauer; Thomas E. Carey; Mark E. Prince
The aim of this study was to investigate oral cancer in pregnant women, a rare but therapeutically challenging patient subset.